Use of methyl-CCNU and procarbazine in advanced malignant melanoma resistant to DTIC therapy

M. S. Didolkar, R. R. Baffi, R. Catane, J. Kaufman, E. D. Holyoke

Research output: Contribution to journalLetterpeer-review

Abstract

When used singly as first agents, both drugs have shown some effect in previous reports; however, when used in combination after failure with DTIC therapy, the responses have been very poor. It appears that 'second attempt' chemotherapy in advanced malignant melanoma results in poor response.

Original languageEnglish (US)
Pages (from-to)1738-1739
Number of pages2
JournalCancer Treatment Reports
Volume61
Issue number9
StatePublished - Dec 1 1977

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Use of methyl-CCNU and procarbazine in advanced malignant melanoma resistant to DTIC therapy'. Together they form a unique fingerprint.

Cite this